Compare CELC & HASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CELC | HASI |
|---|---|---|
| Founded | 2011 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 5.0B |
| IPO Year | 2017 | 2012 |
| Metric | CELC | HASI |
|---|---|---|
| Price | $53.29 | $36.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 15 |
| Target Price | ★ $150.85 | $48.86 |
| AVG Volume (30 Days) | 920.9K | ★ 974.5K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 4.51% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.47 |
| Revenue | N/A | ★ $400,502,000.00 |
| Revenue This Year | N/A | $394.02 |
| Revenue Next Year | $1,921.71 | $12.17 |
| P/E Ratio | ★ N/A | $25.62 |
| Revenue Growth | N/A | ★ 4.41 |
| 52 Week Low | $53.54 | $31.07 |
| 52 Week High | $151.02 | $44.13 |
| Indicator | CELC | HASI |
|---|---|---|
| Relative Strength Index (RSI) | 30.06 | 42.38 |
| Support Level | N/A | $35.58 |
| Resistance Level | $72.76 | $37.34 |
| Average True Range (ATR) | 4.24 | 1.18 |
| MACD | -1.03 | -0.23 |
| Stochastic Oscillator | 0.16 | 0.00 |
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition. The company's single reportable segment generates net investment and equity method investment income through investments in energy transition assets and infrastructure projects, as well as revenue through the gain on sale of assets and recurring asset management fees.